This perspective review explores the transformative potential of personalized herbal medicine, examines the integration of ancient herbal knowledge with modern personalized medicine, delves into the principles of personalized medicine particularly in the context of herbal treatments, and investigates the principles of personalized medicine and elucidates how they are being applied to herbal medicine. It emphasizes the individualized nature of this approach and how it is facilitated through genetic analysis and health profiling. This review also highlights key advancements in herbal medicine, such as deoxyribonucleic acid (DNA) analysis and bioinformatics, and their role in the development of precise and personalized herbal remedies. The outcomes of personalized herbal medicine reveal how genetic variations are being considered to tailor treatments, create target-specific therapies, and customize dosage regimens. Furthermore, this review illustrates the evolution of herbal medicine with technological advancements, particularly DNA analysis and bioinformatics, to enhance precision and personalization. The challenge associated with implementing personalized herbal medicine more broadly includes issues of accessibility, regulation, education and ethics. It underscores the transformative potential of personalized herbal medicine. It calls for continued exploration, research and collaboration in this burgeoning field. This emerging field encourages researchers, practitioners, and stakeholders to engage in advancing healthcare practices that are increasingly personalized, evidence-based, and centered on patient's needs. Please cite this article as: Aslam MS, Kim YJ. Herbal medicine in the modern age: The era of personalized precision. J Integr Med. 2025; 23(6):591-604.
Precision Medicine ; Humans ; Herbal Medicine/methods* ; Phytotherapy

Allergic asthma, a major phenotype of bronchial asthma, shares similarities and differences with non-allergic asthma in its pathogenesis, clinical manifestations, diagnostic approach and criteria, and intervention strategies. The "Chinese guidelines for the diagnosis and treatment of allergic asthma (2019, the first edition)" established a framework for standardizing clinical practice relating to this condition in China. Based on the first edition, this guideline combines recent research progress and novel clinical evidence to supplement and revise the epidemiology, pathogenesis, common allergens, clinical manifestations, diagnostic techniques and standards, treatment and prevention principles of allergic asthma. Key amendments were made to the definition and underlying mechanisms, allergen detection techniques, and endotype assessment. Based on the current landscape of allergic asthma management in China, the updated guidelines provide tailored diagnostic and therapeutic recommendations, especially for allergen-specific immunotherapy, biologic-targeted therapies, and tertiary prevention strategies. A total of 14 evidence-based recommendations are proposed, serving as a clinical reference (guiding document) for optimizing the diagnosis, treatment, and long-term management of allergic asthma in China.
Humans ; Asthma/therapy* ; China ; Allergens ; Practice Guidelines as Topic ; Evidence-Based Medicine

Hemoptysis is a serious medical emergency associated with high mortality rates. Notably, it poses significant therapeutic challenges owing to the complexities in rapidly identifying the bleeding site and underlying cause. In severe cases, it can lead to death by asphyxia, thus necessitating prompt intervention. Bronchoscopy-guided endobronchial balloon occlusion (EBBO) is a vital procedure for blocking the bleeding bronchus, allowing time for subsequent embolization of the responsible vessel and definitive treatment. While traditional techniques for EBBO are intricate and demanding, recent advancements in balloon technology, along with procedural refinements, have simplified the process, reduced operation times, and enhanced medical staff proficiency. Nevertheless, a lack of standardized protocols and technical guidelines has hindered the widespread adoption of this technique in China. Accordingly, the Internal Medicine of Chinese Medical Association convened a group of experts to develop the "Expert consensus on endobronchial balloon occlusion in the treatment of hemoptysis (2025 edition)" to standardize this procedure. This consensus, grounded in evidence-based medicine and clinical practice both domestically and internationally, covers seven essential elements: treatment strategies, equipment, indications and contraindications, preoperative preparation, technical procedures and specifications, integration with other therapeutic techniques, efficacy assessment, and follow-up. By offering comprehensive guidance, the consensus aims to standardize and promote the use of EBBO for hemoptysis management in China.
Humans ; Hemoptysis/therapy* ; Balloon Occlusion/methods* ; Bronchoscopy ; Consensus ; Evidence-Based Medicine

Artificial intelligence (AI) is rapidly advancing in periodontology, bringing new opportunities to clinical diagnosis, risk assessment, personalized treatment planning, and remote patient care. Leveraging core technologies such as deep learning, machine learning, and natural language processing, AI significantly enhances the sensitivity of early periodontal disease detection and provides precise quantification of alveolar bone loss and soft tissue damage. AI facilitates multimodal data integration by synthesizing medical history, lifestyle factors, and imaging data, thereby offering enhanced accurate risk prediction and personalized therapeutic recommendations. By integrating remote monitoring with tailored health counseling, AI helps patients maintain adherence to self-care protocols, significantly improving their oral health-related quality of life and treatment satisfaction. Moreover, AI demonstrates considerable potential in periodontal research and education, particularly in large-scale data mining, virtual clinical case simulations, and natural language processing-assisted literature management. Nevertheless, challenges remain concerning model generalizability, data quality, ethical concerns, and interpretability. The advancement of multi-center big-data platforms is expected to foster a profound integration of AI and periodontology, propelling precision medicine and digital healthcare, enabling holistic management from prevention to long-term care, and enhancing diagnostic efficiency and patient health outcomes.
Humans ; Artificial Intelligence ; Periodontics/methods* ; Periodontal Diseases/therapy* ; Deep Learning ; Precision Medicine ; Quality of Life

The incidence of thyroid cancer keeps rising globally,with the majority being papillary thyroid carcinoma (PTC),which has a favorable prognosis.However,some aggressive PTCs exhibit different clinical behaviors and higher mortality risks,with the growth rate surpassing that of well-differentiated PTC and undifferentiated cancers.Therefore,achieving precise diagnosis and treatment of thyroid carcinoma presents a significant challenge.Photoacoustic imaging is a molecular imaging technology that integrates optical imaging and ultrasound,providing imaging information on structure,function,and molecules.Moreover,it can utilize exogenous contrast agents to realize tumor treatment,such as photothermal therapy,serving as a promising technology for precise diagnosis and treatment of thyroid carcinoma.Researchers both domestically and internationally have explored the application of photoacoustic imaging in the precise diagnosis and treatment of thyroid tumors.This article reviews the research progress,elucidates the advantages and limitations of photoacoustic imaging in the diagnosis and treatment of thyroid carcinoma,and prospects on the precise diagnosis and treatment of this disease.
Humans ; Thyroid Neoplasms/diagnostic imaging* ; Photoacoustic Techniques/methods* ; Precision Medicine

INTRODUCTION

Evidence-based medicine (EBM) integrates clinical expertise, research evidence, and patient preferences to improve care. Despite its significance, challenges in EBM practice persist, particularly in resource-limited settings. This study was done to assess the knowledge, attitudes, practices, and barriers to EBM among resident physicians at Southern Isabela Medical Center (SIMC).

A descriptive cross-sectional study was conducted among 66 resident physicians at SIMC using the validated Evidence-Based Medicine Questionnaire (EBMQ). By purposive sampling, EBMQ was distributed online. Data on demographics, EBM knowledge, attitudes, practices, and barriers were analyzed using frequency and proportions.

The majority demonstrated fair knowledge (50%) of EBM resources and terms, with EBM (from BMJ) being the most utilized EBM-specific resource, and “randomized controlled trials” being the most understood concept. Attitudes were predominantly positive, with 98.5% acknowledging EBM’s role in improving patient care. However, practical application was inconsistent; while 65.2% regularly searched literature, only 43.9% critically appraised evidence. Barriers included limited EBM training and awareness of resources, inadequate facility resources, and patient preferences.

Resident physicians at SIMC possess positive attitudes and fair knowledge of EBM but face challenges in its practical application. Institutional efforts to enhance training, resource access, and infrastructural support are essential to improve EBM practice.

Clinical management of Kawasaki disease faces several challenges, including difficulties in early diagnosis, insufficient personalized treatment, delayed access to information, and inefficient multidisciplinary collaboration. This paper explores the application of the DeepSeek AI model in the management of Kawasaki disease: (1) Enhancing early diagnosis accuracy through the integration and analysis of multimodal data (imaging, laboratory, and clinical data); (2) Dynamically adjusting treatment plans to achieve personalized medicine; (3) Integrating the latest global guidelines and research findings in real-time to optimize clinical processes; (4) Providing personalized health education content to enhance parental involvement; (5) Establishing a platform for sharing clinical data to support intelligent decision-making and multidisciplinary collaboration.
Humans ; Mucocutaneous Lymph Node Syndrome/diagnosis* ; Child ; Artificial Intelligence ; Precision Medicine ; East Asian People

OBJECTIVES: To evaluate and integrate evidence on the management of sleep disorders in children with attention deficit hyperactivity disorder (ADHD). METHODS: Literature was retrieved based on the 6S model, and evidence related to sleep disorder management in children with ADHD was extracted from the included references. RESULTS: A total of 17 studies were included, from which 16 pieces of evidence were extracted. Of these, 6 were classified as Level 1 evidence and 10 as Level 5. The evidence covered screening, assessment, non-pharmacological interventions, pharmacological interventions, follow-up, and multidisciplinary collaboration. CONCLUSIONS This study integrated evidence on the management of sleep disorders in children with ADHD using an evidence-based approach, providing an evidence-based foundation for managing sleep disorders in this population.
Humans ; Attention Deficit Disorder with Hyperactivity/complications* ; Sleep Wake Disorders/etiology* ; Child ; Evidence-Based Medicine

To enhance medication safety and rational use, a multidisciplinary expert panel from the Yangtze River Delta region-comprising specialists in pharmacy, clinical medicine, healthcare administration, and evidence-based medicine-was convened to develop this consensus through multiple rounds of Delphi consultation. A management system for the off-label use of novel antineoplastic agents was established, incorporating a tiered management process and a regional information sharing platform. Standardized procedures were implemented to regulate the applications, review, documentation, and dynamic adjustment of off-label use. The regional platform centralizes the collection and evaluation of evidence for off-label usage, facilitating consistent and homogeneous manage-ment across healthcare institutions. The tiered management process and information sharing platform established herein are intended to serve as a practical reference for standardizing the management of off-label use of novel antineoplastic agents in medical institutions.
Antineoplastic Agents/therapeutic use* ; Humans ; Off-Label Use/standards* ; Consensus ; Evidence-Based Medicine

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine tumor with unique characteristics, and its treatment regimens are primarily derived from those for small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). In recent years, the incidence rate has been on the rise, and the prognosis are affected by the interaction of multiple factors such as individual, clinical stage and treatment mode, and the heterogeneity is significant. In the study of molecular subtypes, multiple subgroups were divided according to key gene mutations such as RB1 and TP53, and genomic subtypes were associated with survival, chemotherapy response, and efficacy of precision therapy. Targeted therapy excavates multiple targets, and the efficacy of drugs is different. Immunotherapy has made remarkable progress, and immune checkpoint inhibitors (ICIs) have been effective in all stages of chemotherapy alone or in combination with chemotherapy or radiation therapy, but there is a risk of hyperprogressive diseases, and accurate prognostic markers need to be explored urgently. This review reviews the latest research progress in the study of molecular subtypes and precision therapies such as targeted therapy and immunotherapy of pulmonary LCNEC, and points out that pulmonary LCNEC treatment will develop in the direction of precision and individualization in the future.
.
Humans ; Lung Neoplasms/drug therapy* ; Carcinoma, Neuroendocrine/drug therapy* ; Precision Medicine ; Immunotherapy ; Carcinoma, Large Cell/drug therapy*